<?xml version='1.0' encoding='utf-8'?>
<document id="26242379"><sentence text="Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib."><entity charOffset="56-66" id="DDI-PubMed.26242379.s1.e0" text="Idelalisib" /></sentence><sentence text="Idelalisib is a potent and selective phosphatidylinositol 3-kinase-δ inhibitor, which is a first-in-class agent to be approved for the treatment of relapsed chronic lymphocytic leukaemia, follicular B cell non-Hodgkin's lymphoma and small lymphocytic lymphoma"><entity charOffset="0-10" id="DDI-PubMed.26242379.s2.e0" text="Idelalisib" /><entity charOffset="37-57" id="DDI-PubMed.26242379.s2.e1" text="phosphatidylinositol" /><pair ddi="false" e1="DDI-PubMed.26242379.s2.e0" e2="DDI-PubMed.26242379.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26242379.s2.e0" e2="DDI-PubMed.26242379.s2.e1" /></sentence><sentence text=" In dose-ranging studies, idelalisib exposure increased in a less than dose-proportional manner, likely because of solubility-limited absorption"><entity charOffset="26-36" id="DDI-PubMed.26242379.s3.e0" text="idelalisib" /></sentence><sentence text=" The approved starting dose of 150 mg twice daily was supported by extensive exposure-response evaluations, with dose reduction to 100 mg twice daily being allowed for specific toxicities" /><sentence text=" Idelalisib may be administered without regard to food on the basis of the absence of clinically relevant food effects, and was accordingly dosed in primary efficacy/safety studies"><entity charOffset="1-11" id="DDI-PubMed.26242379.s5.e0" text="Idelalisib" /></sentence><sentence text=" Idelalisib is metabolized primarily via aldehyde oxidase (AO) and, to a lesser extent, via cytochrome P450 (CYP) 3A"><entity charOffset="1-11" id="DDI-PubMed.26242379.s6.e0" text="Idelalisib" /><entity charOffset="41-49" id="DDI-PubMed.26242379.s6.e1" text="aldehyde" /><pair ddi="false" e1="DDI-PubMed.26242379.s6.e0" e2="DDI-PubMed.26242379.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26242379.s6.e0" e2="DDI-PubMed.26242379.s6.e1" /></sentence><sentence text=" Coadministration with the strong CYP3A inhibitor ketoconazole 400 mg once daily resulted in a ~79 % increase in the idelalisib area under the plasma concentration-time curve (AUC)"><entity charOffset="50-62" id="DDI-PubMed.26242379.s7.e0" text="ketoconazole" /></sentence><sentence text=" Administration with the potent inducer rifampin resulted in a 75 % decrease in idelalisib exposure (AUC) and, as such, coadministration with strong inducers should be avoided"><entity charOffset="40-48" id="DDI-PubMed.26242379.s8.e0" text="rifampin" /></sentence><sentence text=" GS-563117 is an inactive primary circulating metabolite of idelalisib formed mainly via AO"><entity charOffset="60-70" id="DDI-PubMed.26242379.s9.e0" text="idelalisib" /></sentence><sentence text=" Unlike idelalisib, GS-563117 is a mechanism-based inhibitor of CYP3A"><entity charOffset="8-18" id="DDI-PubMed.26242379.s10.e0" text="idelalisib" /><entity charOffset="20-29" id="DDI-PubMed.26242379.s10.e1" text="GS-563117" /><pair ddi="false" e1="DDI-PubMed.26242379.s10.e0" e2="DDI-PubMed.26242379.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26242379.s10.e0" e2="DDI-PubMed.26242379.s10.e1" /></sentence><sentence text=" Accordingly, idelalisib 150 mg twice-daily dosing increases the midazolam AUC 5"><entity charOffset="14-24" id="DDI-PubMed.26242379.s11.e0" text="idelalisib" /></sentence><sentence text="4-fold" /><sentence text=" Clinically, idelalisib is not an inhibitor of the transporters P-glycoprotein, breast cancer resistance protein, organic anion-transporting polypeptide (OATP) 1B1 or OAPT1B3"><entity charOffset="13-23" id="DDI-PubMed.26242379.s13.e0" text="idelalisib" /></sentence><sentence text=" In a population pharmacokinetic model, no meaningful impact on idelalisib pharmacokinetics was noted for any of the covariates tested"><entity charOffset="64-74" id="DDI-PubMed.26242379.s14.e0" text="idelalisib" /></sentence><sentence text=" Idelalisib exposure was ~60 % higher with moderate/severe hepatic impairment; no relevant changes were observed with severe renal impairment"><entity charOffset="1-11" id="DDI-PubMed.26242379.s15.e0" text="Idelalisib" /></sentence><sentence text=" This article reviews a comprehensive pharmacology programme, including drug-drug interaction studies and mechanistic and special population studies, which has allowed a thorough understanding of idelalisib clinical pharmacokinetics and their impact on clinical safety and efficacy"><entity charOffset="196-206" id="DDI-PubMed.26242379.s16.e0" text="idelalisib" /></sentence><sentence text=" " /></document>